Abstract: Functionality of implant surfaces is considerably determined by the conformations of immobilized biomolecules adjustable by the applied surface modification approach. Moreover, surface modification of drug eluting systems often needs to be thoroughly optimized with regard to possible drug losses associated with a loss of functionality. Here, we thoroughly investigate biomolecule surface loading, functionality, morphology and stability in dependence of modification conditions at the example of a site-selective immobilization of anti-CD34 antibodies (CD34-Ab) to drug-eluting stents with the aim of providing general information on the biofunctionalization of drug eluting systems. In this context, we demonstrate that the reaction time of biomolecule immobilization defines achievable surface loads but also drug loss. We could moreover show that the used site-selective immobilization procedure elevated the surface functionality considerably in comparison to surfaces modified by random physisorption. Furthermore investigated bionfunctional stability gives important indications for storage conditions of biofunctionalized implants.
Introduction
The concept of drug eluting stents (DES), allowing the delivery of antiproliferative drugs in a controlled manner to the arterial wall with the purpose to reduce or to prevent excessive neointimal proliferation, has become the mainstay of vascular intervention within the last decade [1] . In comparison to bare metal stents (BMS), envisaging patency of the treated vessel by pure mechanical counteracting the elastic recoil, the clinical outcome regarding major adverse cardiac events (MACE) was improved [2] and in-stent restenosis (ISR) was reduced [3] . However, patients treated with DES can suffer from late stent thrombosis [4] , not seldom leading to severe myocardial infarction or consequently to deceasing. Other studies demonstrated that a more rapid re-endothelialisation of the stented area can lower the risk of inflammation and subsequent thrombus formation [5] . Therefore, novel surface designs allowing in situ endothelialization of the stent surface after implantation were developed. In this context, main attention is drawn to the biofunctionalization of stent surfaces with capture molecules for in vivo circulating endothelial progenitor cells (EPC) presenting an auspicious source of cells with the capacity to differentiate into mature endothelial cells (EC) and to repopulate areas of vascular injury and endothelial disruption [6] . Stents with an immobilized anti-human CD34 antibody are commercially available since 2010 Although CD34 is not a specific marker of EPC, as only a small portion of the CD34-positive cells are actually EPC [7] , first human clinical investigations of this technology demonstrated its safety and feasibility for the treatment of de novo coronary artery disease [8] and the long-term promotion of significant late regression of neointimal hyperplasia [9] . Unfortunately, in spite of these initial promising clinical outcomes, following randomized clinical trials comparing the Genous R-stent with BMS (GENIUS STEMI) [10] and DES (TRIAS) [11] evidenced disappointing results with regard to late luminal loss. These results let to a general discussion of the Genous' clinical efficacy. As reaction to this discussion, the COMBO stent, combining the EPC-capturing anti-CD34 antibody (CD34-Ab) modification with an abluminal elution of sirolimus (SIR), was developed and noninferiority in angiographic in-stent late luminal loss compared to the Taxus Liberté paclitaxel-eluting stent (Boston Scientific, Natick, MA, USA) after 9 months was reported within the REMEDEE trial [12] . The cell selectivity of functionalized implant surfaces as contained on the Geneous or COMBO stent is not only determined by the chosen capture molecules but also by the applied functionalization method. The latter can be underlined by the fact that CD34-Ab immobilized via their fragment crystallizable region (Fc) to ethylene-vinylacetate-(EVA-)coated stainless steel promoted better endothelial cell (EC) attachment in vitro and reduced blood coagulation compared to the same surface, functionalized by the conventional glutaraldehyde treatment [13] . Focusing on biomolecule conformation, we developed a novel stent modification, based on a site-selective immobilization of CD34-Ab to stents, coated with biodegradable poly(L-lactide) (PLLA). Their applicability was investigated in comparison to corresponding BMS and PLLA-coated stents in pigs as an ideal animal model in terms of both the coronary artery tree and its relationship to the myocardium as well as the disposition of neointimal hyperplasia formation [14] . We decided to perform this study with CD34-Ab as model capture molecule, although it is questionable whether it is the adequate capture molecule, as only 0.4±0.2% of CD34 positive cells are EPCs [7] . But in the sense of providing more general information on biofunctionalization methods for drug-eluting devices, which is the superior aim of this study, we assume that the use of a well-described capture molecule is useful. The here performed thorough in vitro characterization of achievable surface loading, functionality, morphology and stability in dependence of modification conditions should give some indications in this context.
Results

Optimization of stent modification regarding CD34-Ab surface load
With the purpose of optimizing conditions for the modification of stents with CD34-Ab, we investigated the influence of CD34-Ab incubation time on achievable antibody surface loads via physisorption and siteselective immobilization by ELISAs. Observed surface loads after site-selective immobilization were at the same level as surface loads achieved via physisorption ( Figure 1A ). Furthermore, while nearly 80% of the maximally observed CD34-Ab load was already obtained after 15 min during site-selective immobilization, physisorption seemed to be slower with 80% reached after 30 min incubation ( Figure 1B ). successful labeling with a FITC-conjugated secondary antibody (insert Figure 3B) . The observed structural integrity of the coating could be maintained after mounting on a balloon catheter and full expansion ( Figure 3C ). Stents, subjected to physical CD34-Ab adsorption had a similar appearance as the here demonstrated surfaces, obtained via site-selective immobilization (data not shown).
CD34-Ag capture efficiency of modified PLLA-coated stents
In order to estimate the CD34-Ag capture capacity of stents, modified with CD34-Ab using previously described conditions, we performed a sandwich ELISA for detection of the achievable antigen surface density. The same
Optimization of stent modification regarding SIR elution
For testing the feasibility of SES functionalization, we examined the SIR recovery as a function of CD34-Ab incubation time. Independently of the immobilization method, loss of SIR progressed with incubation time in a similar manner. For instance after a 30 min incubation, which led to more than 80% of the maximally observed surface load by means of both immobilization protocols, SIR loss from stents to the medium was less than 10% ( Figure 1B ). Of note, the applied plasma-chemical activation of PLLAcoated stent surfaces for the generation of terminal amino groups afforded for covalent antibody binding, did not cause any decrease in SIR content (data not shown).
Additionally performed in vitro release studies of SES, which have been subjected to a 30 min site-selective immobilization of CD34-Ab evidence this loss by a lower amount released within the initial phase of 24 h compared to unmodified SES ( Figure 2 ). However, the slower second release phase revealed a comparable drug release rate (Insert Figure 2) . Antibody incubation time was consequently fixed to 30 min for the following in vitro stent characterization and the in vivo applicability study.
Surface morphology of modified PLLA-coated stents
Following morphological analysis of stent surfaces was performed via electron microscopy. Representative micrographs of stents prior and after site-selective CD34-Ab immobilization reveal a smooth and uniform PLLA coating ( Figure 3A and B). The homogenous antibody modification could be visualized by white spots on stent struts in the ESEM micrographs and by fluorescence microscopy after trend as for CD34-Ab surface load was observed, which is that site-selectively immobilized CD34-Ab lead to higher CD34-Ag densities than randomly physically adsorbed CD34-Ab (Table 1) . For further evaluation, we calculated the average number of captured CD34-Ag per immobilized CD34-Ab and observed that the fraction of CD34-Ab actively involved in the binding of CD34-Ag was significantly higher for stents, modified by site-selective CD34-Ab immobilization versus physisorption. Assuming two antigen-binding sites per CD34-Ab, we estimated that 22%±10% of the physically adsorbed and 56%±11% of site-selectively immobilized CD34-Ab were involved in antigen capture respectively. Independently of the modification, the CD34-Ag capture efficiency as well as the CD34-Ab surface load maintained on modified stents even after mounting on balloon catheter and dilatation with 8 bar (Table 1) .
Stability
Stability of surface loads obtained by site-selective immobilization of CD34-Ab was determined using an ELISA after storage of stents at 4±2°C or 23±2°C in dried condition. Both storage conditions allowed surface load stability for almost half a year, while room temperature seemed to be even more favorable than storage under refrigerated conditions ( Figure 4 ).
In vivo applicability study
The perioperative mortality of stented pigs was zero. No complications occurred during the recovery phase and the 4 weeks post intervention. Quantitative analysis of the coronary artery tissue specimen revealed no significant differences between all three stents (BMS, PLLA, CD34-Ab) with an average restenosis degree of approximately 30% and a neointimal area of about 1.8 mm 2 ( Figure 5 ).
Discussion
Thorough characterization of the antibody functionalization strategy of stents with the purpose to efficiently capture EPC is a crucial step when aiming at improved endothelialization. Not only stability of the immobilized antibodies but also conformation is an important property which might considerably affect their biofunctionality [15] . In this context, various site-selective antibody immobilization protocols have been proposed [16] . For instance, our own research group recently reported on the specific oxidation of the carbohydrate moiety of the antibody, located at the Fc region, with periodate yielding the formation of aldehyde groups for covalent binding to amino-functionalized implant surfaces [17] , which we could now successfully transfer to PLLA-coated stents even with drug-eluting property. As PLLA does however not provide any terminal amino groups and has in general a low natural abundance of functional groups at the surface, a surface activation treatment needs to be performed. While the elsewhere described wet-chemical treatments as silanization [18] , aminolysis [19] and hydrolysis [20] of polyesters are not applicable for drug-eluting systems due to the risk of drug loss, we applied a nonthermal treatment with NH 3 -plasma. Possibly due to the well-known low plasma penetration depth of only 10 nm [21] and the protection of the model drug SIR within the approximately 5 μm thick PLLA-coating on stent struts, no drug loss/degradation was detected after the plasma treatment. Furthermore, the recently reported minimization of nonspecific protein adsorption by hydrophilization of the sample as a result of plasma treatment [17] , might prevent nonspecific cell adhesion and thereby enhance cell specific interaction of immobilized antibodies and support covalent antibody attachment in the following step. The second aspect could be underlined by observed higher surface loads via covalent immobilization in comparison to randomly physisorbed antibodies to previously NH 3 -plasma-activated stents, which reached in maximum 7 ng (data not shown) in comparison to 85 ng by covalent binding. With this method a comparable amount of CD34-Ab could be covalently immobilized as by random physisorption without any previous surface activation treatment ( Figure 1A and Table 1 ), which has been described to occur instantaneously when PLLA is immersed into a protein-containing medium [22] . Interestingly, obtained CD34-Ab surface loads reported on stents here are with a factor of nine considerably higher compared to surface loads on planar PLLA surfaces. For instance, while the physisorption of CD 34-Ab to planar PLLA surfaces resulted in a surface load of 90 fmol/cm 2 [17] , we achieved 816 fmol/cm 2 on stents, assuming a total strut surface of 66 mm 2 , by the same functionalization method. Possibly, strut curvature favors biomolecule immobilization, as also reported for nanoparticles where decreased diameters provoke increased radius curvatures [23] . Moreover, physisorption and covalent binding of CD34-Ab to stents seem to reach a plateau of surface load after 30 min of reaction time under described experimental conditions ( Figure 1A and B). For comparison, kinetic data reported in literature for the adsorption of immunoglobulin G to PLLA show a definite saturation of the surface after ~100 min in presence of a thousand fold of the antibody concentration used here [24] . Reported reaction times reported for reductive amination as used during site-selective covalent binding of the antibody differ from 10 min to 240 h in dependence of the involved carbonyl compound and amine [25] . As the applied reductive agent NaCNBH 3 has a certain specificity for the Schiff base structure, generated by reaction of the oxidized antibody with the amino groups on the surface, it could be immediately added to the reaction medium without affecting the aldehyde groups on the antibody [26] . The short time frame of 30 min is hence the only time, where SIR can be unintendedly eluted from a drug-eluting stent system during the modification procedure. By complete extraction of stents, we detected a SIR loss of 10% ( Figure 1B) . The resulting drug release profile however only evidences a slightly lower drug release rate within the initial phase and no influence on the generally slower second release compared to SES lacking surface modification (Figure 2) . In order to predict whether SIR could still be released from the stent coating in amounts necessary to produce concentrations that inhibit SMC proliferation and migration, we estimated the cumulative SIR concentration released during our in vitro drug release study. With a concentration of 3.0 μM and 3.2 μM prior and after antibody modification, respectively, in literature reported IC 50 values of SIR on SMC proliferation of 1-10 nM [27] were already highly exceeded after the first time interval of 15 min. Therefore, we conclude that chosen experimental conditions for the antibody modification do not alter the antiproliferative activity of the SES relevantly, although the applied mathematical approach does not account for the permanent SIR washing off into the blood stream and accumulation into the vessel wall due to the drug's lipophilic character. Additionally to the SIR elution, we checked for possible influences of the modification procedure on stent surface morphology. As the smooth and uniform PLLA coating was maintained after antibody modification ( Figure 3B ) and moreover preserved during crimping and expansion ( Figure 3C ), influence on stent performance is neither expected from this point of view. In conclusion, both 30 min antibody modification procedures, physisorption and site-selective covalent immobilization, can be applied even on SES. One important advantage of the site-selective approach is however the higher antigen capture capacity with 56 vs. 22% of immobilized CD34-Ab involved in antigen capture capacity (Table 1 ). This fact underlines the successful immobilization of CD34-Ab at postulated sites in opposite to the antigen-binding region. Moreover, the observation corresponds to data presented by other authors, exemplarily stating a consequent increase of the antibody-antigen binding capacity of site-selectively coupled oxidized antibodies on solid-phase supports for immunoaffinity chromatography [28] . Assuming that surfaces exhibit similar capacities for antigen capture and EPC capture, the here established approach for the CD34-Ab immobilization on PLLA, might lead to biodegradable endovascular implant surfaces with considerably improved endothelialization. As evidenced on planar PLLA surfaces, an inclusion of the spacer between antibody and surface might furthermore provide a higher degree of flexibility and hence improved antigen recognition [17] . In that work, we did however apply a further wet-chemical step to incorporate the spacer to the surface, which is not applicable for SES due to the provocation of higher SIR losses. The attachment of a spacer on the antibody would be an alternative to be evaluated. Remarkably, antigen capture capacity as well as antibody surface load was not impaired by stent crimping and expansion, which approves good adherence to the PLLA surface (Table 1) . For the covalently immobilized CD34-Ab we could moreover evidence surface load stability at 4±2°C and 23±2°C for almost half a year (Figure 4) . This underlines the establishment of the stable covalent amide bond, which could be achieved via reduction of the labile Schiff base intermediate primarily formed via the reaction between oxidized CD34-Ab and the aminofunctionalized PLLA surface. After this thorough in vitro optimization and characterization of the proposed novel stent design, involving site-selective CD34-Ab immobilization even applicable for SES; we investigated it is in vivo applicability in comparison to corresponding BMS and PLLA-coated stents in porcine coronary arteries. With a perioperative mortality of zero and no complications occurring during the recovery phase and the 4 weeks' post intervention, applicability could be successfully evidenced. Quantitative analysis of the coronary artery tissue specimen however revealed almost comparable restenosis degrees and neointimal areas independently of the surface modification ( Figure 5 ). Although slow endothelial regrowth has often been associated with increased neointima proliferation [5] , the reverse is not necessarily true. For instance, van Beusekom et al. reported that the Genous R-stent Stent accelerates re-endothelialization without affecting neointimal hyperplasia in porcine coronary arteries [29] . Moreover, one has to consider, that the functionalization during this study as well as of the Genous Stent was performed with anti-human CD34-Ab, whose cross reactivity with porcine CD34 is not well described. Hence, performance of the proposed antibody functionalization regarding efficient promotion of early stent endothelialization, which was not the focus of the present study, requires further investigations.
Conclusion
The presented systematic in vitro characterization of functionalization strategies with CD34-Ab as model capture molecule for DES provides more general information on applicable stent surface modification procedures. For instance, the reaction time of biomolecule (here: CD34-Ab loading) immobilization defines achievable surface loads but also drug loss. As biomolecule surface load is proportional to the surface functionality (here: antigen capture capacity) for each functionalization procedure, time of biomolecule immobilization needs to be thoroughly optimized in order to provide functional surfaces with regard to improved capturing und drug elution. We could moreover show that the used site-selective immobilization procedure elevated the stents surface functionality considerably in comparison to stents modified by random physisorption. Furthermore with the analysis of biomolecule stability after immobilization (room temperature seemed to be even more favorable than storage under refrigerated conditions), important indications for implant storage Site-selective immobilization of CD34-Ab: The afforded generation of terminal amino groups on PLLA-coated stent surfaces was achieved via plasma etching in an ammonia radio frequency (RF) plasma generator (frequency 13.56 MHz, Diener electronic GmbH & Co. KG, Ebhausen, Germany) applying 40 W at a low pressure of 0.3 mbar for 2 min. Prior to subsequent antibody immobilization to amino-activated PLLA-coated stents CD34-Ab were oxidized with sodium periodate (NaIO 4 ). Therefore, 100 μL of 1 mg/mL CD34-Ab solved in acetate buffer (0.02 M sodium acetate, 0.15 M NaCl, pH 5.2 with glacial acetic acid) were mixed with 100 μL of 20 mM NaIO 4 in the same buffer. After incubation for 1 h at 23±2°C protected from light, the resulting CD34-Ab solution was exchanged into fresh DPBS by passage over a Pierce Zeba Spin Desalting Column and the concentration was determined by means of UV-spectroscopy (Biomate 3S, Thermo Scientific, Karlsruhe, Germany) at 205 nm in comparison to a registered calibration line. The surface immobilization of the stents was performed via reductive amination ( Figure 6 ) in 2 mL DPBS containing 1 μg CD34-Ab and 3 μL of 5 M sodium cyanoborohydride (NaCNBH 3 ) for 30 min at 23±2°C. Subsequently, the stents were washed with DPBS containing 0.05% polyoxyethylene (20) sorbitan monolaurate (DPBS/Tween 20). Except during evaluation of optimal parameters optimized from 20 to 120 min with regard to surface load and drug loss the stents were incubated for 30 min.
Characterization
Direct enzyme-linked immunosorbent assay (ELISA) for determination of CD34-Ab surface load: CD34-Ab functionalized stents were immersed in 1 mL of blocking solution (5% w/v skim milk powder in DPBS); stirred for 2 h at 23±2°C and washed with DPBS/0.05% Tween 20. Subsequently, 1 mL of the probe antibody (1 μg/mL, IgG horseradish peroxidase [HRP] conjugate, goat anti-mouse, Jackson ImmunoResearch, UK), diluted in 2 w% skim milk powder in DPBS was added to each stent. Nonspecific interaction of this probe antibodies were examined by ELISA. After stirring for 1 h at 23±2°C and washing with DPBS/0.05% Tween 20 1 mL of 15 μg/mL 3,3′,5,5′-tetramethylbenzidine (TMB) in sodium acetate buffer (pH 5.5) containing 0.004% conditions are given. In summary, provided data serve as a basis for the establishment of novel stent modifications with more promising EPC-capture molecules, as it is questionable whether the well-studied and therefore used CD34-Ab is the adequate capture molecule, and further biofunctionalized implant surfaces.
Materials and methods
Materials
All chemicals were purchased from Sigma-Aldrich (Taufkirchen, Germany), Mallinckrodt Baker (Griesheim, Germany), SERVA Feinbiochemica (Heidelberg, Germany), Thermo Scientific (Karlsruhe, Germany) or Merck (Darmstadt, Germany) in p. a. quality or higher if not indicated differently. Cobalt-chromium (CoCr) stents of 3 mm in diameter and 15 mm in length with a complete surface area of 66 mm 2 and corresponding balloon catheter for stent dilatation were kindly provided by Biotronik SE & Co. KG (Erlangen, Germany). While CD34-Ab (clone 5F3, IgG1, purified mouse, Biozol Diagnostica, Eching, Germany) selected against CD34 partial recombinant protein with GST tag were used during stent modification for in vitro analysis, CD34-Ab (clone 4H11, IgG1, purified mouse, Thermo Scientific, Karlsruhe, Germany) selected against a permanent cell line derived from peripheral leukocytes were used during stent modification for the in vivo study.
Stent modification
Polymer coating: PLLA (Resomer ® L210, M w = 280,000 g/mol, Boehringer Ingelheim, Ingelheim, Germany) was dissolved in chloroform to yield a concentration of 0.25% (w/v). Except for the in vivo applicability testing, SIR was additionally mixed into the polymer solution to obtain a final drug concentration of 17.5% in PLLA (w/w). The polymer solution was afterwards applied to the metallic stent surface via an on-site established spray coating process based on jet atomization technology. Therefore, stents were inserted into a holder of an electropneumatic airbrush system, which guaranteed homogeneous coating by continuous stent rotation along the longitudinal axis. Intermediate weighing using a microbalance (UMX5, Mettler Toledo, Giessen, Germany) during the process allowed the adjustment of the coating mass to 530±20 μg. DES thus yield a total drug load of 1.4 μg/mm 2 in accordance to the SES ORSIRO. Finally, the stents were tempered in vacuum for 13.5 h at 80°C and were sterilized by a common ethylene oxide sterilization process prior to antibody modification under a clean bench.
Physisorption of CD34-Ab: 1 μg of CD34-Ab in 2 mL phosphate buffered saline (Dulbecco's PBS, pH 7.2 [DPBS]) was poured over each PLLA-coated stent and incubated at 23±2°C. Subsequently, stents were washed with DPBS containing 0.05% polyoxyethylene (20) sorbitan monolaurate (DPBS/Tween 20). Except during evaluation of optimal parameters with regard to surface load and drug loss, where incubation time was varied from 20 to 120 min, an incubation time of 30 min was applied. hydrogen peroxide, yielding a blue color when catalyzed by HRP, was added. The reaction was stopped after 10 min with 2 M sulfuric acid (H 2 SO 4 ) in dH 2 O. The absorptions (450 nm) were measured by means of a plate reader. After subtraction of the nonspecific color formation, resulting absorbance values were converted to absolute CD34-Ab loading via comparison to a calibration line performed with known CD34-Ab loadings (0.1-100 ng) in a microtiter well plate, established by overnight incubation of 100 μL DPBS containing the corresponding amounts of CD34-Ab at 4°C. Complete adsorption was proved by analyzing the supernatants after overnight incubation by means of a Mouse IgG1 ELISA Kit (Life Diagnostics, PA, USA).
Sandwich-ELISA for determination of CD34-Ag capture: For the determination of CD34-Ag recognition by immobilized CD34-Ab, modified stents were immersed into 1 mL of blocking solution, stirred for 2 h at 23±2°C and washed with DPBS/0.05% Tween 20. Subsequently, 1 mL of the CD34-Ag (CD34 recombinant protein, 120 ng/mL, GST tag, Biozol Diagnostica, Eching, Germany), diluted in 2% skim milk powder in DPBS, was added to each stent. The mixture was stirred for 2 h at 23±2°C and washed with PBS/0.05% Tween 20. One milliliter of the primary antibody (1 μg/mL, rabbit anti-GST antibody, Abgent, San Diego, USA) diluted in 2% skim milk powder in DPBS, was then added to each stent, stirred for 1 h at 23±2°C and washed with PBS/0.05% Tween 20. Subsequently, 1 mL of the secondary probe antibody (1 μg/mL, IgG HRP conjugate, goat anti-rabbit, Jackson ImmunoResearch, UK), diluted in 2% skim milk powder in DPBS, was added to each stent. The nonspecific interaction of the probe antibodies coupled to the stents was proved by ELISA. Addition of TMB and further treatment was performed analogues to the direct ELISA. After subtraction of the nonspecific color formation, resulting absorbance values were converted to absolute antigen loading via comparison to a calibration line performed with known CD34-Ag loadings (0.1-100 ng) in a microtiter well plate, previously coated with 100 μL of 10 μg/mL CD34-Ab overnight at 4°C. Complete adsorption was proved by analyzing the supernatant after incubation over night by means of the same ELISA.
SIR recovery: During the feasibility study of antibody modification of DES, recovery of SIR from stents was evaluated after the different antibody incubation times. Therefore, stents were extracted two times, first in 10 and then in 4 mL methanol for 30 and 60 min at 23±2°C respectively. 20 μL of each aliquot were injected into an Eurospher 100 C18 column, 120 mm × 4 mm ID (Wissenschaftlicher Gerätebau Dr.-Ing. Herbert Knauer GmbH, Berlin, Germany). The chromatographic conditions were: column temperature 50°C; isocratic eluent acetonitrile/ water 65/35 (v/v); flow rate 1.0 mL/min and UV detection at 278 nm with calibrated measurement range 0.1-10.0 mg/L.
In vitro drug release study: The time course of SIR release was determined at 37°C in 0.9 w% NaCl supplemented with 0.05 w% Brij 35 and 0.003 w% butylated hydroxytoluene (BHT), which assured SIR stability over a time period of in minimum 4 days as determined in preliminary experiments (data not shown). Individual stents (n = 3 in each subgroup) were expanded as described above and subsequently immersed in 2 mL elution medium for a total duration of at least 30 days. The elution medium was renewed at periodic intervals in order to realize sink conditions and avoid a saturation of the medium with drugs. The drug amount released at each time period was determined by high pressure liquid chromatography, applying conditions described above, after 1:1 dilution with methanol. Remaining drug content after the drug release studies was evaluated by extraction of stents as described in the section SIR recovery.
Electron microscopy: The surface morphology of antibody modified stents was assessed by means of a Philips XL 30 ESEM (Philips Electron Optics, Eindhoven, The Netherlands) operating in the ESEM mode. For analysis of the structural integrity after expansion, stents were mounted on 3 × 18 mm balloon catheter and then dilated to their nominal diameter with 8 bar.
Fluorescence microscopy: The antibody modification of stents was proved by fluorescence microscopy (Inverted Microscope Eclipse TE300, Nikon, FL, USA) at λ exc = 450-490 nm and λ em ≥ 520 nm. Prior to fluorescence microscopy, all stents were immersed in 1 mL of blocking solution, stirred for 2 h at 23±2°C, washed with DPBS/0.05% Tween 20 and then labeled with 1 mL of the probe antibody (1 μg/mL in 2 w% skim milk powder in DPBS, IgG fluorescein isothiocyanate (FITC) conjugate, goat anti-mouse, Abcam, UK) for 1 h at 23±2°C with a final washing step in DPBS/0.05% Tween 20.
In vivo applicability study
The following in vivo applicability study was approved by the Landesamt für Landwirtschaft, Lebensmittelsicherheit und Fischerei (LALLF) Mecklenburg-Vorpommern after evaluation and recommendation of the animal welfare committee of Mecklenburg-Vorpommern.
Animals: Ten female pigs of the German Landrace with a weight between 42 and 45 kg were used for a small in vivo study. Prior and after the implantation procedures, animals were kept indoor at a room temperature of about 20°C with a possibility of socializing with other pigs. Besides regular food and water ad libitum a ball and wood pieces to play with were available for the animals. Each of the animals was given 300 mg clopidogrel and 100 mg acetylsalicylic acid (ASA) orally as thrombotic prophylaxis one day before implantation. On the day of surgery all pigs received 75 mg clopidogrel and 100 mg ASA per os. The implantations were performed under general anesthesia, mechanical ventilation and continuous hemodynamic monitoring. After premedication (midazolame 0.2 mg/kg; azaperone 8 mg/kg; ketamine 40 mg/kg, atropine 0.02 mg/kg) and endotracheal intubation the animals were mechanically ventilated by an oxygen (67 vol.%)/isoflurane (0.8-1.5 vol.%) mixture (target parameters: 100-120 mm Hg pO 2 ; 35-40 mm Hg pCO 2 ). Anesthesia was maintained by intravenous administration of fentanyl (0.002 mg/kg·h in 0.9% NaCl solution). Throughout the experiment, the animals were paralyzed by intravenous infusion of pancuronium bromide (25 μg/kg·h in 0.9% NaCl solution). The access to the coronary system was achieved via the left femoral artery using a 6F vascular sheath.
Coronary stenting procedure: After heparinization a 6F guiding catheter (Hockey Stick JR 4) was inserted into the arterial system through the femoral arterial access, advanced to the ascending aorta and positioned selectively in the proximal portions of the left anterior descending coronary artery (LAD), the right circumflex artery (RCX) and the right coronary artery (RCA). The designated coronary segments were displayed by injection of 5 mL contrast medium (Ultravist-150; Bayer Healthcare AG, Berlin, Germany) and coronary angiography (Ziehm Vario 3D; Ziehm Imaging, Nürnberg, Germany).
Thereafter, a crimped stent on a deflated balloon angioplasty catheter was brought into the preselected artery and implanted by inflation of the balloon catheter for 30 s under a pressure of 5-10 atm in order to achieve a 1.1 to 1 stent-to-vessel diameter ratio. The procedure was done under radiographic control ( Figure 7A ) with placement of the BMS into the RCA, the PLLA-coated stent (PLLA) into the LDA and the antibody-functionalized stent (CD34-Ab) into the RCX in each pig. The stent apposition was controlled by intravascular ultrasound. Subsequently the guiding catheter and the introduced sheath were removed, the femoral artery ligated with 3-0 vicryl (Ethicon, Norderstedt, Germany) and the incision closed in two layers (subcutis and cutis) with 3-0 vicryl. All animals received a daily oral medication of 75 mg clopidogrel and 100 mg ASA for prevention of intracoronary stent-associated thrombus. If necessary, postoperative analgesia with 10 mg/kg novaminsulfone was performed to ameliorate suffering.
Procedure of stent harvest: After 4 weeks there was the final examination of the stented coronary arteries by angiography. The ventilation and anesthesia regimen corresponded to the procedure during stent implantation. Prior to euthanasia the anesthesia was deepened by the analgesic fentanyl (5 μg/kg). In addition pancuronium bromide (0.15 mg/kg bolus, continuous infusion 150 μg/kg·h) was applied as a muscle relaxant. After sternotomy and inserting an appropriate retractor pigs were euthanized by intravenous injection of 3 M KCl. Subsequently the hearts were dissected as follows: removal of the pericardium at the transition pericardium to epicardium, disconnecting and severing of aorta with its branches, pulmonary trunk with right and left pulmonary artery (pulmonary artery and vein), lower vena cava, upper vena cava and the pulmonary veins. After washing in physiological sodium chloride solution, hearts were fixed in 4% formaldehyde. Subsequently the stented vessel segments were excised from the coronaries and embedded in a plastic matrix (Technovit 7200, Heraeus Kulzer, Wehrheim, Germany).
Histomorphologic analysis: From the Technovit 7200 blocks, in which the vessel segments were embedded, rough grinding preparations with a thickness of 100-150 μm were made. Upon a subsequent grind down process up to 50 μm and deplastination, hematoxylin and eosin (H&E) staining followed ( Figure 7B ). The morphological analysis was performed by planimetric assessment of the neointima and media thickness above and below as well as between the several struts according to Kornowski et al. [30] . Furthermore the original luminal circumference, which follows the internal elastic membrane, and the relative luminal circumference, that describes the new endothelial border, were identified for calculation of the degree of restenosis by using the software ImageJ (version 1.45s; http://imagej. nih.gov/ij) as previously described [30] .
Statistics: Statistical analysis was performed by analysis if variance (ANOVA), followed by the appropriate post-hoc comparison test, using the software SigmaStat (Jandel, San Rafael, CA, USA). A p-value < 0.05 was considered to be statistically significant. 
